MetaVia Unveils Promising Obesity Treatments at ADA 2026 Conference

MetaVia Inc., a biotechnology company focused on cardiometabolic diseases, has revealed that three key abstracts have been accepted for presentation at the American Diabetes Association (ADA) 2026 Scientific Sessions. These late-breaking abstracts spotlight the company’s innovative treatments: DA-1726, a dual GLP-1/glucagon agonist, and vanoglipel, a GPR119 agonist. The conference is scheduled for June 5-8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Highlights of the Presentations

The three presented abstracts will delve into the efficacy and safety profiles of these novel treatments, emphasizing their roles in managing obesity and its related complications. This representation marks a significant achievement for MetaVia as it underscores the potential effectiveness and innovation of their cardiometabolic portfolio.

1. DA-1726 Abstract

The first of these abstracts includes a detailed analysis of DA-1726, which serves as a novel oxyntomodulin (OXM) analogue. It is designed to interact with both the GLP-1 receptor (GLP1R) and glucagon receptor (GCGR), contributing to appetite suppression and increased energy expenditure—key factors in weight management.

Study Focus: Assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726.
Presenting Author: Weikai